Hypoesthesia

Geisinger enrolls first patient in amyloid cardiomyopathy trial

Retrieved on:

пятница, мая 10, 2024

DANVILLE, Pa., May 10, 2024 /PRNewswire/ -- Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial.

Key Points:

DANVILLE, Pa., May 10, 2024 /PRNewswire/ -- Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial.
"If a patient qualifies for the clinical trial, it will allow us to provide a treatment option when they receive an amyloidosis diagnosis without having to travel outside of the region for care," said Dr.
"Geisinger is at the forefront of research and technological advancements that allow for better patient outcomes and improvements in their quality of life."
The trial is a phase 3, randomized, double-blind, placebo-controlled study that evaluates the safety and effectiveness of amyloid deplete ALXN2220 in participants with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Retrieved on:

среда, мая 8, 2024

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

Key Points:

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.
The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups.
After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd.
Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships.

Facet Replacement Fda Study Garners Best Paper Award At Lumbar Spine Research Society Meeting

Retrieved on:

четверг, мая 2, 2024

Stenosis, FDA, Patient, Spine, Spinal stenosis, Back pain, MD, Research, LSRS, Spondylolisthesis, Sciatica, Spinal fusion, Hypoesthesia, Annual general meeting, Quality of life, Walking, Overalls, CE

NORWALK, Conn., May 2, 2024 /PRNewswire-PRWeb/ --Premia Spine, a leader in innovative spinal treatment solutions, today announced that the pioneering study titled "Lumbar Facet Arthroplasty for Degenerative Spondylolisthesis with Stenosis: Interim Analysis of Three-Year Outcomes from a Prospective Randomized Clinical Trial" has been awarded the prestigious Best Paper at the Lumbar Spine Research Society (LSRS) 2024 Annual Meeting. The award-winning study, reported by Zachariah Pinter, MD, showcased the significant advantages of facet replacement over traditional lumbar fusion.

Key Points:

Premia Spine's study on the TOPS® System, showcasing its advantages over traditional lumbar fusion, received the Best Paper award at the LSRS 2024 Annual Meeting.
NORWALK, Conn., May 2, 2024 /PRNewswire-PRWeb/ --Premia Spine, a leader in innovative spinal treatment solutions, today announced that the pioneering study titled "Lumbar Facet Arthroplasty for Degenerative Spondylolisthesis with Stenosis: Interim Analysis of Three-Year Outcomes from a Prospective Randomized Clinical Trial" has been awarded the prestigious Best Paper at the Lumbar Spine Research Society (LSRS) 2024 Annual Meeting .
The award-winning study, reported by Zachariah Pinter, MD, showcased the significant advantages of facet replacement over traditional lumbar fusion.
The research involved 300 patients who were prospectively randomized across thirty-seven centers to receive either the Total Posterior Spine (TOPS) facet joint replacement system or a TLIF lumbar fusion.

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

Retrieved on:

вторник, апреля 16, 2024

Pain, Electrode, SCS, Epidural space, Neurological disorder, Animal, Diabetes, CGM, Electricity, Doctor of Philosophy, Blood, PDN, Patient, Spinal cord stimulator, Spinal cord, Glucose, Hypoesthesia, Quality of life, Medical device

Rutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space. A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).

Key Points:

A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).
Combining SCS and continuous glucose monitoring (CGM) could provide several possible advantages, such as simplifying device management for those patients.
This is the second application of Glucotrack’s technology for implantable continuous glucose monitoring, in addition to its development of a long-term Continuous Blood Glucose Monitoring (CBGM) system.
The results demonstrated the Glucotrack epidural glucose values closely tracked both the blood glucose and subcutaneous CGM values.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on:

вторник, марта 26, 2024

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points:

The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
“Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

Treace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient Milestone

Retrieved on:

понедельник, марта 25, 2024

ABC, Hypoesthesia, Patient, Education, Foot, Bunion, Chronic pain, Quality of life, Life, Surgeon, Woman, Arthritis, Radio, Diving, Pain, Recurrence, Swelling, Parent

PONTE VEDRA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that 100,000 patients have been treated with its patented Lapiplasty® 3D Bunion Correction® System.1 This milestone coincides with the first-ever National Bunion Day in the United States, which is being sponsored by Treace on April 16, 2024, and the launch of its new patient education and brand awareness campaign.

Key Points:

“Achieving this important milestone is a testament to the tireless efforts of our team members and the trust of our surgeon customers and patients, all of whom have made our journey possible,” said John T. Treace, CEO and Founder of Treace.
“Since our initial surgical cases in 2015, Treace has been committed to educating people about surgical options that can provide lasting relief from bunion pain through our innovative procedures that are designed to minimize recovery time, reduce recurrence rates, and improve patient outcomes.
Today the Company also unveiled its latest campaign to continue to drive patient education and awareness of its Lapiplasty® Procedure.
Treace will premiere the “Future You” commercial on the finale of “The Bachelor” TV show on March 25, 2024 at 8:00 p.m. Eastern Time on the ABC network.

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Retrieved on:

вторник, марта 5, 2024

Spleen, Liver, Bangladesh Technical Education Board, Autoimmune disease, NIH, Physician, Extrapyramidal system, Weight loss, Dizziness, AL amyloidosis, Amyloidosis, Diagnosis, Joint, Hypoesthesia, Fatigue, Patient, Heart, Tissue, Mortality

LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced its new AL Amyloidosis awareness campaign Be Proactive in AL™.

Key Points:

LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced its new AL Amyloidosis awareness campaign Be Proactive in AL™.
The campaign seeks to increase awareness about the critical need to recognize and diagnose AL Amyloidosis early, while also educating AL Amyloidosis patients about available treatment options.
AL amyloidosis is a life-threatening immunological disorder in which an abnormal protein called amyloid builds up in tissues and organs.
“Today, it is common for AL Amyloidosis patients to see 3 or 4 different physicians and wait months to years before being definitively diagnosed with AL amyloidosis,” said Dena Heath, Amyloidosis Research Consortium Board Secretary and Facilitator, Northern California Amyloidosis Support Group.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on:

вторник, марта 5, 2024

Senior, Tenderness, Infection, Dizziness, AbbVie, XC, Lidocaine, Swelling, Exercise, Skin, Pregnancy, History, Cyst, Red, HIV/AIDS, Trial of the century, Allergy, Social media, Incidence, Neck, Dermatology, Aspirin, Pain, Forehead, Stroke, Hyaluronic acid, Pimple, Pigment, Ibuprofen, Scar, Rash, Anaphylaxis, Chin, Learning, Weakness, Safety, Filler (linguistics), DSM-IV codes, Hypoesthesia, Clinical trial, Paratriathlon, Bleeding, Face, Jaw, ABBV, Injection, Bruise, AMI, Inflammation, FDA, TSR, U.S. FDA, Confusion, Risk, Steroid, Patient, Tell, Wound, Gram, HIV, Cheek

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points:

*1
"The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
"This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on:

вторник, марта 5, 2024

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points:

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.

How Cinesteam® Helps Manage Smells From Diabetic Foot

Retrieved on:

четверг, февраля 29, 2024

Diabetes, Smell, Blood, Diabetic foot, Sensation, Pain, Infection, Foot, Diabetic neuropathy, Ulcer, Blister, Mayo Clinic, Peripheral neuropathy, Hypoesthesia, Business, Code, Dentistry

FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes. The condition can lead to chronic wounds that produce highly unpleasant smells. Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.

Key Points:

FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes.
Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.
The medical condition comes with many health concerns, one of which is commonly referred to as "diabetic foot."
Mayo Clinic reports that as much as 50% of those with diabetes can be affected by diabetic neuropathy, opening the doors for diabetic foot to develop.